About CHEORS
CHEORS is a Healthcare company based in North Wales (United States) founded in 2015, and was acquired by PharmAlliance in April 2024. It operates as a HEOR solutions are provided for pharmaceutical and biotech industries. The company has 22 employees. Its chief executive is Mark Bouck. Its Indian entity Complete Heor Solutions India Private Limited reported revenue of ₹20.97 Cr. Its focus areas include Biopharma Outsourcing and Diversified. Its competitors include Eurofins Scientific, WuXi AppTec, Ipsen, CHEPLAPHARM and ANI Pharmaceuticals and 4 more; 3 of its 9 listed competitors have raised funding.
Company details
CHEORS was founded in 2015 and is based in North Wales, United States. Health economics outcomes and research solutions are offered to the pharmaceutical and biotech sectors, with a focus on market access services, early decision models, and customized payer tools. The company was recently acquired by PharmAlliance, through which operations in the healthcare industry are continued.
- Headquarters North Wales, United States
- Employees 22
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cheors.com
- Social LinkedIn X
- Acquired by PharmAlliance (Apr 2024)
- Legal Name Complete Heor Solutions India Private Limited
- Date of Incorporation 23 Jun, 2015
- Jurisdiction New Delhi, Delhi, India
- Annual Revenue₹20.97 Cr
FY 2025 · +13% YoY
- Net Profit₹2.63 Cr
FY 2025 · 13% margin
- EBITDA₹3.61 Cr
FY 2025 · 17% margin
- Investors
- Employee Count22
- Acquired byPharmAlliance
(Apr 2024)
Associated legal entities of CHEORS
CHEORS operates through Complete Heor Solutions India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Complete Heor Solutions India Private Limited CIN U74140DL2015FTC281882 | Active | 23 Jun 2015 | New Delhi, Delhi | ₹21.0 Cr | 22 | 5 | View details |
Investors in CHEORS
CHEORS has secured backing from 1 investor. Prominent investors backing the company include PharmAlliance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | pharmallianceportfolio.com | - |
Investor details for CHEORS
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Complete Heor Solutions India Private Limited (CHEORS)
Complete Heor Solutions India Private Limited is the primary company behind CHEORS. The board of Complete Heor Solutions India Private Limited currently have 5 directors; the longest-serving is Jagdeep Singh, appointed in 2015. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Jagdeep Singh DIN 00024905 | Nominee Director | 23 Jun 2015 | 11 yrs 3 mo | Complete Heor Solutions India Private Limited |
| Manmohan Singh Bagga DIN 07159093 | Nominee Director | 23 Jun 2015 | 11 yrs 3 mo | Complete Heor Solutions India Private Limited |
| Mark Andrew Bouck DIN 10737730 | Director | 10 Aug 2024 | 2 yrs 2 mo | Complete Heor Solutions India Private Limited |
| Jennifer Petra Boscia DIN 11039932 | Additional Director | 04 Apr 2025 | 1 yr 6 mo | Complete Heor Solutions India Private Limited |
| Punith Ramchandra Kundran DIN 10876453 | Additional Director | 13 Feb 2026 | 8 mo | Complete Heor Solutions India Private Limited |
People of CHEORS
1 people are tracked at CHEORS (1 in leadership); the tracked headcount is 22.
| Name | Role | Group |
|---|---|---|
| CEO | Leadership |
Complete people profiles for CHEORS
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of CHEORS
Figures of Complete Heor Solutions India Private Limited, the primary company behind CHEORS, for FY 2025. Revenue was ₹20.97 Cr (+13% year on year). Net profit was ₹2.63 Cr (13% margin). EBITDA was ₹3.61 Cr (17% margin). Revenue has grown at a compounded annual rate of +22% over three years and +19% over five years.
- ₹20.97 CrRevenue · FY 2025 · +13% YoY
- ₹2.63 CrNet profit · 13% margin
- ₹3.61 CrEBITDA · 17% margin
- ₹1 LakhPaid-up capital
- 22Employees (provident fund records)
- +22%Revenue CAGR, 3 years
- +19%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Complete Heor Solutions India Private Limited are on its company page.
Detailed financial statements for CHEORS
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of CHEORS
2 dated milestones of CHEORS across 9 years, from founding to its latest funding, stage changes and deals.
- Founded CHEORS is founded.
- Exit Acquired by PharmAlliance.
Competitors of CHEORS
CHEORS has 9 listed competitors in our database, 3 of them funded. They include Eurofins Scientific, WuXi AppTec, Ipsen, CHEPLAPHARM and ANI Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| eurofins.com | 1987 | Luxembourg | – | – | Laboratory testing and contract research services are provided globally. | |
| wuxiapptec.com | 2000 | Shanghai, China | $40M | 1,681 | Provider of CRO and CDMO services | |
| ipsen.com | 1929 | – | – | 505 | Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes | |
| cheplapharm.com | 1998 | Mesekenhagen, Germany | – | 840 | Branded pharmaceutical products are developed, marketed, and distributed globally. | |
| anipharmaceuticals.com | 1996 | Baudette, United States | – | 600 | Branded and generic prescription drugs are developed, manufactured, and marketed. | |
| caidya.com | 2003 | Morrisville, United States | $373M | 351 | CRO focused on clinical development for phases II & III clinical trials and regulatory affair services | |
| rednucleus.com | 2014 | Yardley, United States | – | 176 | Advisory, scientific, and medical communications provided for pharmaceutical industry. | |
| aptar.com | 1992 | Crystal Lake, United States | – | 232 | Regulatory support, brand differentiation, and prototyping services are provided. | |
| aliadatx.com | 2021 | Boston, United States | $33M | – | Provider of drug research & development services for multiple therapeutic areas |
Detailed competitors of CHEORS
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
10 companies that operate in the same segment as CHEORS (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cheors
Complete news archive for CHEORS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CHEORS
CHEORS was founded in 2015.
CHEORS is headquartered in North Wales, United States. It is registered at North Wales, Pennsylvania, United States.
Mark Bouck is the current CEO of CHEORS.
CHEORS has 22 employees.
The primary company behind CHEORS, Complete Heor Solutions India Private Limited, reported revenue of ₹20.97 Cr for FY 2025, up 13% year on year.
CHEORS was founded in 2015 and is based in North Wales, United States. Health economics outcomes and research solutions are offered to the pharmaceutical and biotech sectors, with a focus on market access services, early decision models, and customized payer tools. The company was recently acquired by PharmAlliance, through which operations in the healthcare industry are continued.
CHEORS's top competitors include WuXi AppTec, ANI Pharmaceuticals and Aptar.
CHEORS has 1 investor. Key investors include PharmAlliance.
CHEORS operates through Complete Heor Solutions India Private Limited.
Yes. CHEORS was acquired by PharmAlliance in April 2024.
The legal entities of CHEORS currently have 5 directors, including Jagdeep Singh, Mark Andrew Bouck, Manmohan Singh Bagga and others.